🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesShould I be worried about my heart rate going up? — anyone have experience? Page 3

Should I be worried about my heart rate going up? — anyone have experience?

fiona_VT Tue, Nov 12, 2024 at 3:46 AM 12 replies 1,852 viewsPage 3 of 3
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Nov 13, 2024 at 8:08 AM#11
claudia_zurich said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely!

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

Last edited: Nov 13, 2024 at 9:08 AM
22 20pete_manc_UK, anna.melb_AU, mark_tokyo and 19 others
Reply Quote Save Share Report
jason_sac26
New Member
34
123
Jan 2026
Sacramento, CA
Nov 13, 2024 at 10:51 PM#12
Dr.DermMIA said:
Dr.PainCLE said: ...we're creating a generation dependent on cardiovascular risk...

Thank you for spelling out the reasoning rather than just the conclusion. Adding it to my notes with a link back to this thread.

Last edited: Nov 14, 2024 at 12:51 AM
23 21Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 20 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Nov 14, 2024 at 1:33 PM#13
claudia_zurich said:
Positive "side effect" of cardiovascular risk: my blood pressure dropped so much that I'm now off amlodipine entirely!

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
Last edited: Nov 14, 2024 at 5:33 PM
24 22AussieAnna, BethLabQueen, ChrisMacros and 21 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
lucas_SP_BR
Member
456
1,890
Jun 2024
São Paulo, BR
Nov 15, 2024 at 4:15 AM#14
fiona_VT said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 49" → 37" ✅ Resolved
  2. Triglycerides: 251 → 96 ✅ Resolved
  3. HDL: 33 → 53 ✅ Resolved
  4. Blood pressure: 141/93 → 119/73 ✅ Resolved
  5. Fasting glucose: 116 → 85 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

25 23KarenAZ_mom, zoe_NC, Dr.ObesityLA and 22 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Nov 15, 2024 at 6:57 PM#15

Moderator note: a couple of off-topic posts removed.

Last edited: Nov 15, 2024 at 10:57 PM
26 24PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 23 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register